Nanobiotix is trading at $31.34, down 7.16% now, with no clear company-specific announcement explaining the October 30 decline.
- The latest listed company release was an October 24 clinical-data update.
- The Nasdaq Composite fell 1.4% in Thursday’s session, and Friday reporting described U.S. stocks as lower.
- Broader market weakness may be contributing, but available evidence does not establish it as the direct cause.